{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:41Z","timestamp":1790983121604,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05880-y","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:45:37Z","timestamp":1788147937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acetazolamide and topiramate-induced clinically significant metabolic acidosis and weight loss in idiopathic intracranial hypertension: a case report and pharmacovigilance analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6967-487X","authenticated-orcid":false,"given":"Berke","family":"\u015eent\u00fcrk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3543-3733","authenticated-orcid":false,"given":"Eda","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1048-0324","authenticated-orcid":false,"given":"Hatice Nur","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1397-7472","authenticated-orcid":false,"given":"Berivan","family":"Yakut-\u00d6ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1843-3424","authenticated-orcid":false,"given":"H\u00fclya","family":"Tezel-Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5110-0937","authenticated-orcid":false,"given":"Berke","family":"Cural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-8997","authenticated-orcid":false,"given":"Lale","family":"\u00d6z\u0131\u015f\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-8727","authenticated-orcid":false,"given":"Nadir","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"3","key":"5880_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/medicina61030450","volume":"61","author":"A Almaqhawi","year":"2025","unstructured":"Almaqhawi A, Alokley A, Alamri R, Alabdulqader R, Alali A, Aleid A, Alhejji A, ALNasser MN (2025) Effectiveness of topiramate versus acetazolamide in the management of idiopathic intracranial hypertension: a systematic review and meta-analysis. Medicina (Kaunas) 61(3):450","journal-title":"Medicina (Kaunas)"},{"key":"5880_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.otc.2025.12.008","volume":"59","author":"A Bailey","year":"2026","unstructured":"Bailey A, Stevens SM, Knievel KL (2026) Idiopathic intracranial hypertension. Otolaryngol Clin North Am 59:485\u2013496","journal-title":"Otolaryngol Clin North Am"},{"key":"5880_CR3","doi-asserted-by":"publisher","unstructured":"Belanger K, Ashraf O, Rau J, Hui F, Fargen KM Challenges in the management of idiopathic intracranial hypertension. J Neurointerv Surg (online ahead of print). https:\/\/doi.org\/10.1136\/jnis-2025-024599","DOI":"10.1136\/jnis-2025-024599"},{"key":"5880_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster O, Aoki Y, Gattepaille LM, Grundmark B (2020) Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf 43:479\u2013487","journal-title":"Drug Saf"},{"key":"5880_CR5","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.2014.3312","volume":"311","author":"NIIHSGW Committee","year":"2014","unstructured":"Committee NIIHSGW, Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ (2014) Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 311:1641\u20131651","journal-title":"JAMA"},{"key":"5880_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/WNO.0000000000000813","volume":"39","author":"F Costello","year":"2019","unstructured":"Costello F, Skolnik K, Sarna J, Varughese R (2019) Respiratory Complications Associated With Acetazolamide Use in the Management of Idiopathic Intracranial Hypertension. J Neuroophthalmol 39:511\u2013512","journal-title":"J Neuroophthalmol"},{"key":"5880_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5880_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Noren GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf 47:575\u2013584","journal-title":"Drug Saf"},{"key":"5880_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035545","volume":"102","author":"A Goyal","year":"2023","unstructured":"Goyal A, Zarroli K (2023) Should topiramate be initial therapy in the management of idiopathic intracranial hypertension?: a literature review. Medicine (Baltimore) 102:e35545","journal-title":"Medicine (Baltimore)"},{"key":"5880_CR10","first-page":"107","volume":"35","author":"O Gungor Tuncer","year":"2023","unstructured":"Gungor Tuncer O, Nalbantoglu M, Sengul EA, Baykan B (2023) Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. Agri 35:107\u2013110","journal-title":"Agri"},{"key":"5880_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"JR Horn","year":"2007","unstructured":"Horn JR, Hansten PD, Chan LN (2007) Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 41:674\u2013680","journal-title":"Ann Pharmacother"},{"key":"5880_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pediatrneurol.2024.06.015","volume":"160","author":"J Jeon-Chapman","year":"2024","unstructured":"Jeon-Chapman J, Estrela T, Heidary G, Gise R (2024) Efficacy and side effects of topiramate in treatment of children with pseudotumor cerebri syndrome. Pediatr Neurol 160:32\u201337","journal-title":"Pediatr Neurol"},{"key":"5880_CR13","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1111\/j.1467-789X.2010.00846.x","volume":"12","author":"CK Kramer","year":"2011","unstructured":"Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL (2011) Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev 12:e338-347","journal-title":"Obes Rev"},{"key":"5880_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrneph.2010.33","volume":"6","author":"JA Kraut","year":"2010","unstructured":"Kraut JA, Madias NE (2010) Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol 6:274\u2013285","journal-title":"Nat Rev Nephrol"},{"key":"5880_CR15","unstructured":"Wolters Kluwer Clinical Drug Information, Inc. (2026) Acetazolamide and topiramate drug interaction analysis. Lexi-Interact Online. https:\/\/online.lexi.com. Accessed 5 Aug 2026"},{"key":"5880_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/EB.S492845","volume":"17","author":"J Naqvi","year":"2025","unstructured":"Naqvi J, Wall M, Chung SM, Thurtell M, Linton E, Rodriguez-Barrath A, Kardon R (2025) Acetazolamide for idiopathic intracranial hypertension: an up-to-date review in 2025. Eye Brain 17:125\u2013136","journal-title":"Eye Brain"},{"key":"5880_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"},{"key":"5880_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05880-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05880-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05880-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:45:40Z","timestamp":1788147940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05880-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":18,"alternative-id":["5880"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05880-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"17 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this study. The pharmacovigilance analysis was conducted using fully anonymized, publicly available data from the FDA Adverse Event Monitoring System (AEMS), which does not constitute human subject\u2019s research. The case report portion was conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written and verbal informed consent for the publication of clinical details, laboratory results, and any accompanying data was obtained directly from the patient. A copy of the written consent is available for review by the Editor-in-Chief of this journal upon request.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}